We have previously demonstrated that Mycobacterium leprae-burdened granuloma macrophages isolated from infected nude mice are refractory to activation by gamma interferon (IFN--y). To explore further both the afferent and efferent functional capacity of M. leprae-infected macrophages, we examined the IFN-y-mediated activation of resident mouse peritoneal macrophages infected in vitro with live or dead M. leprae. When IFN-,y was administered within 24 h of M. leprae infection, macrophages were fully activated. However, defective activation was evident at 3 to 5 days postinfection in macrophages that were heavily burdened with viable M. leprae. This defect was evident by four parameters of activation in which IFN-,y failed to stimulate the enhancement of microbicidal activity, cytotoxicity for tumor target cells, 02-production, and surface Ia antigen expression. The development of defective activation closely followed an increase in macrophage production of prostaglandin E2. Defective activation of M. leprae-burdened macrophages was reversible by indomethacin, and a similar block in IFN-'y activation was observed in three of these four parameters in normal macrophages treated with exogenous prostaglandin E2. Thus, infection of mouse macrophages with M. leprae appears to restrict IFN-y-mediated activation at least in part by induction of inhibitory levels of prostaglandin E2.
A prominent feature of lepromatous leprosy is the presence of macrophage-rich granulomas that harbor large numbers of intracellular Mycobacterium leprae. Previous studies have established that human peripheral blood monocytes from leprosy patients have a normal microbicidal capacity (8) and responsiveness to gamma interferon (IFN--y) (16, 18, 27) . However, this finding may not be true of tissue macrophages within the local lesion, of which little is known regarding functional capacity. We have recently demonstrated that macrophages isolated from lepromatous granulomas of M. leprae-infected nude mice are completely refractory to activation by IFN--y (39, 40) . This nonresponsive condition appears to be dependent on the heavy intracellular load of bacilli found in localized granulomas since peritoneal macrophages from these same mice are activated normally by IFN--y.
Previous studies have demonstrated that uptake of live M. leprae may lead to a reduction of macrophage protein metabolism (34) , reduced expression of surface receptors for Fc (3) , and surface sialic acid residues (1) . However, these studies have not addressed the consequence of M. leprae infection on the principal afferent and efferent functions of the macrophage in conferring cell-mediated resistance to intracellular microorganisms, i.e., antigen presentation and enhanced microbicidal capacity. In the present study, we have used normal mouse peritoneal macrophages to examine the development of defective macrophage activation as a consequence of in vitro infection with live versus dead M. leprae. The functional capacity of macrophages was evaluated by measuring an enhanced capacity for killing of the intracellular protozoan Toxoplasma gondii, enhanced cytostatic capacity for EL-4 tumor target cells, enhanced respiratory burst activity, and increased Ta receptor expres- sion. These varied responses are functionally distinct in their mechanisms of action but share the common feature of being induced by IFN-y in combination with low levels of endotoxin that together act as potent macrophage-activating signals (4, 20, 26, 29, 33) . In addition, based on our previous observations that lepromatous granuloma macrophages produce elevated levels of prostaglandin E2 (PGE2) (40) , we have examined the role of this inhibitory immunomodulator on macrophage activation.
MATERIALS AND METHODS
Cell culture. Resident peritoneal macrophages were collected from adult BALB/c or Swiss Webster mice and cultured on LUX cover slips (Miles Scientific, Div. Miles Laboratories, Inc., Naperville, Ill.) in 24-well plates at 2 x 106 cells per well or on Lab-Tek chamber slides (Miles) in complete medium as described previously (39, 40) . Complete medium consisted of RPMI 1640 (GIBCO Laboratories, Grand Island, N.Y.) supplemented with 1 mM glutamine (Irvine Scientific, Santa Ana, Calif.), 25 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer (GIBCO), and 100 U of penicillin (Sigma Chemical Co., St. Louis, Mo.) per ml containing 20% heat inactivated fetal bovine serum (FBS) (Sterile Systems, Inc., Logan, Utah). Tissue culture media and reagents used in this study contained .0.025 ng of endotoxin per ml as detected by the chromogenic Limulus amoebocyte assay (Whittaker MA Bioproducts, Walkersville, Md.). Indomethacin (Sigma) was prepared as a stock solution in 1.0 mg/ml in dimethyl sulfoxide and stored at -70°C. PGE2 (10-3 M; Seragen, Inc., Boston, Mass.) and phorbol myristic acetate (PMA; 10 ,ug/ ml; Sigma) were prepared as stock solutions in absolute ethanol and stored at -70°C.
In Vitro Infection with M. leprae. M. leprae cells were obtained from log-phase growth in the nude mouse footpad (7) and were purified as described previously (12, 37) . Briefly, infected footpads were minced in sterile Dubos albumin, pH 6.0, homogenized with a ground-glass homogenizer, and clarified by low-speed centrifugation at 100 x g for 10 min at 4°C to remove large tissue fragments and aggregates. The resulting suspension was pelleted at 2,700 x g for 60 min at 4°C, and the pellet was suspended in cold Dubos albumin. Live M. leprae suspensions were stored at 4°C and used within 48 h of harvest. Freshly harvested M. leprae cells were killed by treating for 12 h with 10% Formalin followed by five washings in Dubos albumin by centrifugation at 2,700 x g for 60 min. Control M. leprae cells were washed in parallel. M. Ieprae cells were counted by the method of Shepard and McRae (36) and diluted into complete medium for challenge of macrophage monolayers. Monolayers were allowed to phagocytose M. leprae until the mean number of intracellular bacilli reached levels of approximately 10 intracellular M. leprae per macrophage for examining effects of low burdens and approximately 50 intracellular M. leprae for examining the effects of high burdens of infection. Monolayers were then rinsed extensively in Hanks balanced salt solution (Whittaker) and recultured in RPMI-20% FBS. Challenge doses of live and Formalin-killed M. leprae were adjusted to obtain equal intracellular burdens in macrophages. Viability of macrophage monolayers was monitored by ethidium bromideacridine orange staining as described previously (39) .
PGE2 production. To monitor production of PGE2 by macrophage cultures, 1.0-ml supernatants were harvested at 1, 3, 5, and 7 days, clarified at 10,000 x g for 10 min at 4°C, and stored at -70°C. Control supernatants were harvested from cultures incubated with 1.0 ,ug of indomethacin per ml to inhibit prostaglandin synthesis. For analysis (40) , 100-,ul samples were incubated at 37°C, pH 10.0, for 24 h to convert PGE2 to its stable end product bicyclo-PGE2. Bicyclo-PGE2 was quantitated for triplicate tubes per sample, using a radioimmunoassay kit (New England Nuclear Corp., Boston, Mass.).
PGE2 treatment. 
RESULTS
Production of PGE2. To examine the unstimulated production of PGE2 by normal and M. leprae-infected macrophages, supernatants were collected at intervals following in vitro cultivation. Due to the extremely short half-life of PGE2 (13), production was monitored indirectly by quantifying the accumulation of the stable breakdown product bicyclo-PGE2. Although this method does not allow precise determination of PGE2 concentrations, the relative production during an extended interval is reflected by accumulation of bicyclo-PGE2. Normal macrophages produced basal lev- (Fig. 1) . By comparison, RPMI-20% FBS used to culture macrophages contained 0.02 ng of bicyclo-PGE2 per ml. Macrophages infected with viable M. leprae underwent a burst of PGE2 production at day 2 to 3 after infection that reached levels of 2.6 ng/ml per 106 cells (approximately M) (Fig. 1) . The burst of PGE2 production was not related to the initial phagocytosis of bacilli and returned to levels observed in noninfected cells by day 7 in culture. Treatment of M. leprae-infected macrophages with 1.0 ,ug of indomethacin per ml blocked the elevated production of PGE2 (Fig.  1 ). Macrophages challenged with Formalin-killed M. leprae showed normal levels of bicyclo-PGE2 production throughout this period of culture (Fig. 1) M. leprae-burdened macrophages cultured for 3 to 5 days in vitro prior to stimulation by IFN--y was examined further by using both the induction of toxoplasmacidal activity and additional criteria of IFN--y-mediated activation. The inclusion of these additional criteria was designed to test whether the inhibition of macrophage responsiveness was limited to expression of enhanced microbicidal activity or was a generalized failure to respond to IFN-y. To assess the importance of M. leprae viability, macrophages were infected with either live or Formalin-killed M. leprae. These experiments also addressed the influence of PGE2 on macrophage activation in normal macrophages treated for 3 days with exogenous PGE2 at 108 M, a level that simulated the production of PGE2 in M. leprae-burdened macrophages. Also, some cultures of M. leprae-burdened macrophages were treated with 1.0 ,ug of indomethacin per ml to suppress prostaglandin synthesis.
(i) Microbicidal activity. Normal macrophages treated with IFN--y and low doses of endotoxin after 3 to 5 days of culture were activated as demonstrated by their capacity to restrict the intracellular growth of T. gondii (Fig. 2) . However, macrophages treated with PGE2 or macrophages infected in vitro with viable M. leprae showed significantly lower activation by IFN--y as reflected by the increased growth of T. gondii (P c 0.01 versus normal macrophages treated with IFN--y; Fig. 2 ). Decreased activation of IFN--y-treated macrophages infected with viable M. leprae was reversed by coculture in 1.0 ,ug of indomethacin per ml (Fig. 2) . Indomethacin treatment did not affect the toxoplasmacidal capacity of normal macrophages activated with IFN-y (not shown). Macrophages infected with Formalin-killed M. leprae showed normal activation for restriction of T. gondii growth (Fig. 2) . In the absence of IFN--y treatment, T. gondii growth was not affected by indomethacin or PGE2, nor did M. leprae infection of untreated macrophages affect the growth of T. gondii (Fig. 2) .
(ii) Cytostatic activity. Normal macrophages cultured for 3 to 5 days and then treated with IFN--y and low levels of endotoxin were activated to restrict the uptake of [H] thymidine by EL-4 tumor target cells (P c 0.001) (Fig. 3) . In contrast, IFN--y-mediated activation for cytostatic activity was significantly lower in macrophages that were treated in vitro with exogenous PGE2 or in those infected with viable M. leprae (P s 0.001 versus normal macrophages treated with IFN--y; Fig. 3 ). This defect in activation of macrophages infected with live M. Ieprae was reversed by coculture in 1.0 ,ug of indomethacin per ml and was not observed in macrophages infected in vitro with Formalin-killed M. leprae ( normal macrophages activated with IFN--y (not shown). In the absence of IFN--y stimulation, EL-4 proliferation was not affected by coculture with PGE2-treated macrophages, M. leprae-infected macrophages, or indomethacin-treated macrophages (Fig. 3) . (iii) 02-production. Normal macrophages cultured for 3 to 5 days and then treated with IFN--y demonstrated increased capacity to secrete 02 when stimulated with PMA (P ' 0.01) (Fig. 4) . However, IFN--y-induced production of 02 was significantly inhibited in macrophages infected in vitro with viable M. leprae (P c 0.05 versus normal macrophages treated with IFN-y) (Fig. 4) . This defect was reversed when M. leprae-infected cells were cocultured in 1.0 ,ug of indomethacin per ml (Fig. 4) . Macrophages treated in vitro with exogenous PGE2 or infected with Formalin-killed M. leprae showed normal induction of 02 production when stimulated with IFN--y (Fig. 4) . Indomethacin treatment did not affect 02 production by normal macrophages activated with IFN--y (not shown). In the absence of IFN--y treatment, macrophage 02 production was not affected by indomethacin, PGE2, or M. leprae infection (Fig. 4) .
(iv) Ia antigen expression. Expression of lad antigens by macrophages following in vitro culture is summarized in defective responses to IFN-y were not observed in recently infected macrophages (24 h or less) but was consistently seen when macrophages harbored leprosy bacilli for 3 to 5 days before stimulation with IFN--y. While we have not directly examined the effects of varying concentrations of IFN--y or endotoxin in this report, these studies were conducted with doses of IFN--y and endotoxin well above the threshold necessary to induce activation in normal macrophages (39, 40) .
The development of defective activation was closely correlated with elevated PGE2 production by live M. lepraeinfected macrophages that peaked at 48 to 72 h postinfection at a level of approximately 10-8 M. However, when M.
leprae-infected macrophages were cocultured with 1.0 jig of indomethacin per ml, prostaglandin production was reduced to normal levels and IFN--y-mediated activation was restored to normal. It was previously shown that PGE2 does not inhibit IFN--y activation for enhanced tumoricidal activity when these two modulators were added simultaneously (43) . However, in the present report, when macrophages were pulsed with repeated doses of exogenous PGE2 for intervals of 3 to 4 days prior to IFN-y activation, their capacity to become activated was severely restricted. The defect in activation produced by repeated PGE2 treatments was evident as a reduction in microbicidal and tumoricidal capacity and as inhibition of IFN-y-induced Ia expression. These findings are consistent with previous reports that PGE2 inhibits induction of macrophage Ia expression by lymphokines (42) and demonstrate that prolonged exposure to PGE2 inhibits the expression of macrophage effector functions normally enhanced by IFN--y. Moreover, a single dose of exogenous PGE2 significantly decreased macrophage activation when given 2 to 3 days prior to, but not after, being given simultaneously with IFN--y treatment. This finding correlates with our observation that the burst of PGE2 production induced by infection with live M. leprae was followed 1 or 2 days later by reduced responsiveness to IFN--y.
Collectively, the present findings demonstrate a role for induction of PGE2 production leading to decreased capacity for activation as a major consequence of M. leprae infection in mouse peritoneal macrophages. A similar role for heightened production of PGE2 by macrophages leading to in vivo immune suppression has recently been demonstrated for M. intracellulare infection in mice (9) . In addition to the generalized block in macrophage activation induced by live M. leprae (39, 40 ; present report), Leishmania donovani (31) , Mycobacterium microti (19) , and Mycobacterium kansasii (Mshana et In the present study, elevated levels of PGE2 induced by infection with live M. leprae were correlated with reduced macrophage activation as evaluated by toxoplasmicidal and tumoristatic activity and by expression of Ia antigens. However, although PMA-triggered respiratory burst activity by IFN--y-stimulated macrophages was reduced in M. lepraeinfected macrophages, their unresponsiveness could not be induced by addition of exogenous PGE2. While elevated respiratory burst activity has been correlated with the enhanced cytotoxic and microbicidal state of activated macrophages, this correlation is not universal (6, 17, 41) . The disassociation observed between the role of PGE2 in unresponsiveness to IFN--y enhancement of efferent and afferent induction of respiratory function and the failure of PGE2 to block IFN--y burst activity may reflect a different underlying mechanism in the induction of these responses by IFN--y. Regardless, the uptake of M. leprae by macrophages is a very poor activator of the respiratory burst (15) , suggesting that even slight inhibition of the respiratory burst may be important for intracellular survival.
In contrast to the findings that heavily burdened macrophages are refractory to further activation by IFN-y (39, 40 ; present report), macrophages treated with immune lymphokines, including IFN-y, prior to encountering M. leprae attain an activated state and significantly inhibit the intracellular metabolism and survival of M. leprae (37; N. Ramasesh, S. Franzblau, and J. Krahenbuhl, manuscript in preparation). In the present study, the development of defective activation was not simply a consequence of phagocytosis or early events following the ingestion of live bacilli but was delayed 72 to 96 h. Collectively, these findings underscore the importance of the timing of macrophage uptake of viable M. leprae in relationship with the capacity for IFN--ymediated activation. Thus, the development of defective activation in infected macrophages observed in the present report appears to be dependent on the accumulative influence of an intracellular burden of live M. leprae. Whether IFN--y activation is blocked by a threshold dose of an actively synthesized constituent of live leprosy bacilli is under investigation. In recent preliminary studies (38), we have reported that lipoarabinomannan, an abundant, highly immunogenic component of the mycobacterial cell wall, is a potent inhibitor of IFN--y-mediated activation of mouse macrophages by mechanisms that do not appear to involve production of PGE2.
In M. leprae-infected nude mice, defective macrophage activation is confined to heavily burdened macrophages isolated from granulomas of the footpad and lymph nodes, whereas peritoneal macrophages from these same mice exhibit normal IFN-y responsiveness (39, 40) . Although the lepromatous macrophages isolated from granulomas in the nude mouse produce high levels of PGE2, the failure of indomethacin treatment to restore IFN-y activation of these lepromatous macrophages (40) suggests that nonprostanoid mechanisms of inhibition are also involved in the restriction of their activation. While the underlying basis of this defect is not known, the present report emphasizes the importance of heightened PGE2 production by M. leprae-infected macrophages in leading to compromised responsiveness to activating signals. Thus, newly arrived bone-marrow-derived monocytes likely encounter conditions in the localized lepromatous granuloma that rapidly restrict their responsiveness to IFN--y.
We have recently examined the content of PGE2 in supernatants produced by in vitro cultivation of skin biopsies from the lesions of leprosy patients that were initially collected for studies of local modulation of monocyte leucotactic responses (5) . Preliminary analyses (Sibley and Krahenbuhl, unpublished results) indicate that supernatants from unstimulated biopsies from both borderline and lepromatous leprosy patients contain elevated ievels of PGE2. Elevated levels of PGE2 have been shown to dramatically influence a number of T-cell and macrophage functions, including inhibition of T-cell proliferation (10), suppression of Ia antigen expression by macrophages treated with lymphokines (42) , and inhibition of macrophage tumoricidal capacity (43) . Although the local cellular source of the elevated POE2 production in lesions of leprosy patients is not known, the abundance of macrophages in these lesions and the induction of PGE2 production by human monocytes exposed to M. leprae in vitro (32) implicate the M. lepraeinfected macrophage. Support for this hypothesis is provided by studies that use a mouse model of experimental leprosy which show elevated spontaneous release of PGE2 in vitro by M. leprae-infected macrophages (present study) and in vivo by M. leprae-burdened macrophages from local lepromatous granulomas (39, 40) . Studies on the production of arachidonic acid metabolites by stimulated human monocytes indicate that thromboxane rather than PGE2 is the predominate cyclooxygenase metabolite (30) . Thus, while PGE2 may be an important local mediator in the response of mouse macrophages to M. leprae, the role of PGE2, thromboxane, and other arachidonic acid metabolites in modulating human macrophage responses in leprosy will require further study.
With the exception of their inability to cope with the leprosy bacillus, macrophages from lepromatous patients are functionally normal as evidenced by the in vitro microbicidal capacity of peripheral blood monocytes (8) and the observation that these patients are not susceptible to the facultative and obligate intracellular pathogens characteristically seen in the immunocompromised host. Although monocytes from lepromatous patients appear to produce lower levels of the oxidative metabolite H202, this function is restored following in vivo (27) or in vitro (18) administration of IFN-,y. Moreover, enhanced microbicidal capacity for Legionella pneumophila is induced in vitro by IFN-,y in monocytederived macrophages from lepromatous patients (16) . Thus, while peripheral blood monocytes of leprosy patients appear to be functionally normal in their microbicidal capacity and their responsiveness to IFN--y (8, 16, 18, 27) , their arrival in the granulomatous lesion may lead to exposure to conditions which inhibit their capacity to respond to macrophageactivating signals. Previous studies of cell-mediated responses of leprosy patients have emphasized the importance of T-cell anergy that results in lowered production of interleukin-2 and IFN-y (14, 16, 28) and fewer interleukin-2+ lymphocytes (23) and the role of suppressor T cells (22, 24, 25) as a mechanism underlying this specific anergy. In this context, it is noteworthy that PGE2 has been shown to preferentially encourage T suppressor rather than helper cell proliferation (11) . Collectively, our studies of the interaction of M. leprae with mouse macrophages (39, 40 ; present report) emphasize that defects in cell-mediated immunity in lepromatous leprosy likely extend beyond the level of the T cell to include localized restriction of macrophage afferent and efferent functions influenced by lymphokines. 
